Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
McKesson
Dow
Colorcon

Last Updated: August 14, 2022

Investigational Drug Information for Tartaric acid


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Tartaric acid?

Tartaric acid is an investigational drug.

There have been 10 clinical trials for Tartaric acid. The most recent clinical trial was a Phase 2 trial, which was initiated on January 3rd 2020.

The most common disease conditions in clinical trials are Hodgkin Disease, Atrial Fibrillation, and Hyperuricemia. The leading clinical trial sponsors are Boehringer Ingelheim, Mirati Therapeutics Inc., and Shiraz University of Medical Sciences.

There are six hundred and forty-seven US patents protecting this investigational drug and nineteen international patents.

Recent Clinical Trials for Tartaric acid
TitleSponsorPhase
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With CoronavirusHospital EspanholPhase 2
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With CoronavirusSENAI CIMATECPhase 2
A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy VolunteersHamilton Health Sciences CorporationPhase 4

See all Tartaric acid clinical trials

Clinical Trial Summary for Tartaric acid

Top disease conditions for Tartaric acid
Top clinical trial sponsors for Tartaric acid

See all Tartaric acid clinical trials

US Patents for Tartaric acid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tartaric acid See Plans and Pricing Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) See Plans and Pricing
Tartaric acid See Plans and Pricing Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) See Plans and Pricing
Tartaric acid See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tartaric acid

Drugname Country Document Number Estimated Expiration Related US Patent
Tartaric acid World Intellectual Property Organization (WIPO) WO2013170005 2032-05-11 See Plans and Pricing
Tartaric acid World Intellectual Property Organization (WIPO) WO2016085784 2034-11-26 See Plans and Pricing
Tartaric acid European Patent Office EP3197455 2034-09-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
McKesson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.